| Document |
Document Title |
|
WO/2020/056714A1 |
A method for preparing high-purity riboflavin sodium phosphate, comprising: adjusting the pH value to 5.0-7.0; controlling the solution temperature at 20-40℃, and adding an ethanol aqueous solution with a concentration of 95％ (ml/ml)...
|
|
WO/2020/051207A2 |
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...
|
|
WO/2020/033823A1 |
The present invention relates to the discovery of novel 2-amino-dihydropteridinone compounds and analogues thereof capable of inhibiting phosphatidylinositol phosphate kinases. In certain embodiments, the compounds of the invention can b...
|
|
WO/2020/007834A1 |
The present inventionrefers to a crystalline salt comprising5-methyl-(6S)- tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of -methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3...
|
|
WO/2020/007839A1 |
The present inventionrefers to a crystalline salt comprising5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/m...
|
|
WO/2020/007841A1 |
The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in m...
|
|
WO/2020/007836A1 |
The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (...
|
|
WO/2020/007843A1 |
The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethylester, wherein the molar ratio of 5-methyl-(6S)-tetrahyd...
|
|
WO/2019/232120A1 |
The present invention relates to new pharmaceutical salts and/or co-crystals of sepiapterin which exhibit improved properties. In particular, the invention relates to salts of sepiapterin with improved stability. The invention also relat...
|
|
WO/2019/209757A1 |
The present invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for reating cellular proliferate disorders (e.g. cancer).
|
|
WO/2019/200120A1 |
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.
|
|
WO/2019/178677A1 |
The present disclosure relates to the targeted delivery of defined active agents and/or immunomodulatory agents to lymph nodes or lipoid cells in a lymphatic tissue. More particularly, the invention provides methods for targeted delivery...
|
|
WO/2019/161963A1 |
The present invention provides a method of stabilising a biological sample comprising at least two folate species. The method comprises providing the biological sample and contacting the folate species with a reducing agent and an alipha...
|
|
WO/2019/160736A1 |
The disclosure relates generally to gamma polyglutamated pralatrexate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated pralatrexate, and methods of making and using the gamma polyglutamated ...
|
|
WO/2019/160734A1 |
The disclosure relates generally to gamma polyglutamated lometrexol compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated lometrexol, and methods of making and using the gamma polyglutamated lome...
|
|
WO/2019/160735A1 |
The disclosure relates generally to gamma polyglutamated tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated tetrahydrofolate, and methods of making and using the gamma polyglu...
|
|
WO/2019/160733A1 |
The disclosure relates generally to gamma polyglutamated methotrexate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated methotrexate, and methods of making and using the gamma polyglutamated ...
|
|
WO/2019/160732A1 |
The disclosure relates generally to gamma polyglutamated aminopterin compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated aminopterin, and methods of making and using the gamma polyglutamated am...
|
|
WO/2019/157146A1 |
The disclosure relates generally to alpha polyglutamated Antifolates, formulations containing liposomes filled with alpha polyglutamated Antifolates, methods of making the alpha polyglutamated Antifolates and liposome containing formulat...
|
|
WO/2019/157138A1 |
The disclosure relates generally to alpha polyglutamated pemetrexed, formulations containing liposomes filled with alpha polyglutamated pemetrexed, methods of making the alpha polyglutamated pemetrexed and liposome containing formulation...
|
|
WO/2019/157133A1 |
The disclosure relates generally to alpha polyglutamated raltitrexed, formulations containing liposomes filled with alpha polyglutamated raltitrexed, methods of making the alpha polyglutamated raltitrexed and liposome containing formulat...
|
|
WO/2019/157140A1 |
The disclosure relates generally to gamma polyglutamated raltitrexed compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated raltitrexed, and methods of making and using the gamma polyglutamated ra...
|
|
WO/2019/157129A1 |
The disclosure relates generally to alpha polyglutamated pralatrexate, formulations containing liposomes filled with alpha polyglutamated pralatrexate, methods of making the alpha polyglutamated pralatrexate and liposome containing formu...
|
|
WO/2019/157145A1 |
The disclosure relates generally to gamma polyglutamated pemetrexed compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated pemetrexed, and methods of making and using the gamma polyglutamated peme...
|
|
WO/2019/157121A1 |
The disclosure relates generally to alpha polyglutamated lometrexol, formulations containing liposomes filled with alpha polyglutamated lometrexol, methods of making the alpha polyglutamated lometrexol and liposome containing formulation...
|
|
WO/2019/157120A1 |
The disclosure relates generally to polyglutamated alpha tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the polyglutamated alpha tetrahydrofolate, and methods of making and using the polyglutamate...
|
|
WO/2019/157123A1 |
The disclosure relates generally to alpha polyglutamated aminopterin, formulations containing liposomes filled with alpha polyglutamated aminopterin, methods of making the alpha polyglutamated aminopterin and liposome containing formulat...
|
|
WO/2019/157125A1 |
The disclosure relates generally to alpha polyglutamated methotrexate, formulations containing liposomes filled with alpha polyglutamated methotrexate, methods of making the alpha polyglutamated methotrexate and liposome containing formu...
|
|
WO/2019/157148A1 |
The disclosure relates generally to gamma polyglutamated Antifolate, formulations containing liposomes filled with gamma polyglutamated Antifolate, methods of making the gamma polyglutamated Antifolate and liposome containing formulation...
|
|
WO/2019/113685A1 |
Micelle-forming amphiphilic block copolymers for use in targeting cardiac cells (e.g. fibrotic cells) of a subject suffering from heart failure, micelles containing the micelle-forming amphiphilic block copolymers together with a cardioa...
|
|
WO/2019/111136A1 |
The present invention relates to a topical pharmaceutical composition containing of about 0.01 % w/w to about 0.1 % w/w of methotrexate in topical solution form for external use for the treatment of psoriasis. The present invention also ...
|
|
WO/2019/076675A1 |
This invention relates to the finding that the inhibition of solute carrier family 6 member 2 (Slc6a2) exert a sympathomimetic effect outside the brain that promotes weight loss without concomitant hypophagia or hyperkinesia. Compounds f...
|
|
WO/2019/067782A1 |
Given its various activities in the brain, nitric oxide (NO) has been associated with various neuropsychiatric diseases and/or neuropsychiatric disorders, including schizophrenia. In fact, evidence has been accumulating to show that abno...
|
|
WO/2019/063236A1 |
The invention relates to amorphous folate salt. The salt consists of a folate anion and an organic cation. The folate anion is selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid,...
|
|
WO/2019/034673A1 |
The present invention is directed to stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydro folic acid or a pharmaceutically acceptable salt thereof and a dicarboxylic acid, or a salt thereof, as well as, a processes of obtaining...
|
|
WO/2019/029541A1 |
Provided are a fibroblast growth factor receptor (FGFR) irreversible inhibitor as represented by formula I, a pharmaceutically acceptable salt, a stereoisomer thereof, and pharmaceutical preparations, pharmaceutical compositions and uses...
|
|
WO/2019/016397A1 |
The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.
|
|
WO/2018/229261A1 |
The invention relates to a prodrug compound consisting of a drug moiety comprising an amine or hydroxyl moiety and a protecting group moiety covalently linked to the amine or hydroxyl moiety. The drug moiety is effective in the treatment...
|
|
WO/2018/217651A1 |
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
|
|
WO/2018/178141A1 |
The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)- tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solv...
|
|
WO/2018/178142A1 |
The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio...
|
|
WO/2018/178144A1 |
The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)- tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:1.51 to 1:2.5 and/or hydrates and/or solvates thereof...
|
|
WO/2018/172243A1 |
The present invention is directed towards isomerically pure 18F-labelled (6S)-or (6R)-5-methyltetrahydrofolate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18F-labelled N-heterocycle...
|
|
WO/2018/153507A1 |
Compounds of formula (I), wherein R', R'', R, X, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
|
|
WO/2018/130865A1 |
A composition for treating headaches and migraines and methods of using same for preventative use to decrease the frequency, duration and severity of headaches and migraines in children and adults.
|
|
WO/2018/113584A1 |
Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and ca...
|
|
WO/2018/102314A1 |
Disclosed is a crystalline form of sepiapterin, a method of preparing the crystalline form, pharmaceutical compositions containing the crystalline form, and a method for treating patients with a disease associated with low intracellular ...
|
|
WO/2018/071531A1 |
The disclosure provides linked purine pterin compounds of Formula I that are novel inhibitors of HPPK, a kinase responsible for an essential step in the biosynthesis of folic acid. (Formula I) The variables, e.g., A1-A3, R1-R4, B1-B2, an...
|
|
WO/2018/058091A1 |
Described herein are divalent nucleobases that each binds two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone, such as in a γ-peptide nucleic acid (γPNA). Also provided ...
|
|
WO/2018/031967A1 |
The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with the polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and meth...
|
